Paul Reider
Corporate Officer/Principal presso COHERUS BIOSCIENCES, INC.
Patrimonio netto: 194 252 $ in data 31/03/2024
Profilo
Paul Reider is a member of the Clinical Advisory Board at Tetraphase Pharmaceuticals, Inc. He is also the Chief Commercial Officer at Coherus BioSciences, Inc. starting in 2022.
Previously, he worked as the Vice President of Sales & Strategic Accounts at Puma Biotechnology, Inc. from 2019 to 2021.
He also held a position as the General Manager at Ipsen Biopharmaceuticals Canada, Inc. Mr. Reider completed his undergraduate degree and MBA at Bowling Green State University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 20/01/2024 | 81 277 ( 0.07% ) | 194 252 $ | 31/03/2024 |
Posizioni attive di Paul Reider
| Società | Posizione | Inizio |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01/01/2021 |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Precedenti posizioni note di Paul Reider
| Società | Posizione | Fine |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Sales & Marketing | 01/01/2021 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | - |
Formazione di Paul Reider
| Bowling Green State University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
- Borsa valori
- Insiders
- Paul Reider
